THE ASSIGNMENT (1–2 PAGES) Recommend one FDA-approved drug, one off-label drug, and one nonpharmacological intervention for treating your assigned disorder in children and adolescents. Explain the risk assessment you would use to inform your treatment decision making. What are the risks and benefits of the FDA-approved medicine? What are the risks and benefits of the off-label drug? Explain whether clinical practice guidelines exist for this disorder and, if so, use them to justify your recommendations. If not, explain what information you would need to take into consideration. Support your reasoning with at least three scholarly resources, one each on the FDA-approved drug, the off-label, and a non-medication intervention for the disorder. Attach the PDFs of your sources.

Major Depressive Disorder FDA-approved drug: In the treatment of pediatric depression, selective serotonin reuptake inhibitors (SSRIs) are typically used as the first-line medication. According to Selph and McDonagh (2019), the FDA has authorized the use of fluoxetine for the treatment of major depressive disorder (MDD) in children and adolescents between the ages of 7 and 17. Children with MDD are typically given fluoxetine 10 or 20 mg daily. As soon as 10 mg/day has been used effectively for a week, a dose increase to 20 mg/day may be considered. After several weeks with no clinical changes, an increase to 20 mg daily is considered. Off-label Drug: The Food and Drug Administration (FDA) has approved fluvoxamine for the treatment of OCD in adolescents and young adults (those between the ages of 8 and 17). Nevertheless, it is used off-label to treat MDD in young people. According to Dwyer & Bloch (2019), to achieve its therapeutic effect, the medication blocks the reuptake of serotonin in the presynaptic nerve terminals. Initiating treatment with Fluvoxamine in children is suggested to begin with a single 25-mg dose taken at bedtime. Children's dosages are prescribed taking into account age and gender variances. Children under the age of 11 are given a daily dose that does not exceed 200 milligrams. The therapeutic effect can often be achieved in females at lower doses. Adjusting the dosage for teenagers (up to the maximum adult dose of 300 mg) can produce therapeutic effects. Non-pharmacological Intervention: The first-line treatment for MDD in children is typically psychotherapy. Cognitive-behavioral therapy is among the most successful forms of talk therapy (CBT). The interplay between actions, emotions, and thoughts constitutes the bedrock of cognitive-behavioral therapy. Patients are taught to recognize negative thought patterns and

Order this paper